{"id":"taf-based-regimen-tbr","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Elevated creatinine"}]},"_chembl":{"chemblId":"CHEMBL324631","moleculeType":"Small molecule","molecularWeight":"643.29"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"TAF is a prodrug of tenofovir that achieves higher intracellular concentrations with lower systemic exposure compared to TDF (tenofovir disoproxil fumarate). When used as part of a combination antiretroviral regimen (TBR), it inhibits HIV reverse transcriptase, preventing conversion of viral RNA to DNA and blocking viral replication. TAF-based regimens typically include additional antiretroviral agents such as integrase inhibitors or protease inhibitors to provide potent combination therapy.","oneSentence":"TAF (tenofovir alafenamide) is a nucleotide reverse transcriptase inhibitor that blocks HIV reverse transcriptase to prevent viral replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:37:16.628Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced adults (as part of combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT03446573","phase":"PHASE3","title":"Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-01-18","conditions":"HIV Infections","enrollment":743}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TAF based regimen (TBR)","genericName":"TAF based regimen (TBR)","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TAF (tenofovir alafenamide) is a nucleotide reverse transcriptase inhibitor that blocks HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults (as part of combination antiretroviral therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}